These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 34848946

  • 1. Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway.
    Wu X, Zhao K, Fang X, Lu F, Zhang W, Song X, Chen L, Sun J, Chen H.
    Drug Des Devel Ther; 2021; 15():4741-4757. PubMed ID: 34848946
    [Abstract] [Full Text] [Related]

  • 2. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
    Liu FL, Chen CL, Lai CC, Lee CC, Chang DM.
    Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
    [Abstract] [Full Text] [Related]

  • 3. Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs.
    Kats A, Gerasimcik N, Näreoja T, Nederberg J, Grenlöv S, Lagnöhed E, Desai S, Andersson G, Yucel-Lindberg T.
    J Cell Mol Med; 2019 Feb; 23(2):1152-1163. PubMed ID: 30506812
    [Abstract] [Full Text] [Related]

  • 4. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway.
    Yang J, Tang R, Yi J, Chen Y, Li X, Yu T, Fei J.
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [Abstract] [Full Text] [Related]

  • 5. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways.
    Zhou C, Liu W, He W, Wang H, Chen Q, Song H.
    Int Immunopharmacol; 2015 Mar; 25(1):49-54. PubMed ID: 25617149
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M, Shan J, Xu H, Xia G, Xu Q, Quan K, Liu X, Dai M.
    J Ethnopharmacol; 2021 Aug 10; 276():114176. PubMed ID: 33933570
    [Abstract] [Full Text] [Related]

  • 8. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC, Lee C, Kim JY, Oh HM, So HS, Lee MS, Rho MC, Oh J.
    Biol Pharm Bull; 2013 Aug 10; 36(11):1779-86. PubMed ID: 23985829
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
    Baek JM, Kim JY, Yoon KH, Oh J, Lee MS.
    Int J Biol Sci; 2016 Aug 10; 12(5):478-88. PubMed ID: 27019631
    [Abstract] [Full Text] [Related]

  • 12. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L, Yang M, Shrestha SK, Kim H, Gerwick WH, Soh Y.
    Int J Mol Sci; 2021 Feb 25; 22(5):. PubMed ID: 33669069
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oxysophocarpine attenuates inflammatory osteolysis by modulating the NF-κb pathway and the reactive oxygen species-related Nrf2 signaling pathway.
    Shi X, Gao T, Yu C, Fu S, Guo T, Xu W, Li X, Wang Y, Zhang J, Jia X, Mao Y.
    Inflammopharmacology; 2024 Oct 25; 32(5):3461-3474. PubMed ID: 39150492
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY, Cheon YH, Oh HM, Rho MC, Erkhembaatar M, Kim MS, Lee CH, Kim JJ, Choi MK, Yoon KH, Lee MS, Oh J.
    Bone; 2014 Mar 25; 60():104-11. PubMed ID: 24361669
    [Abstract] [Full Text] [Related]

  • 18. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhai ZJ, Li HW, Liu GW, Qu XH, Tian B, Yan W, Lin Z, Tang TT, Qin A, Dai KR.
    Br J Pharmacol; 2014 Feb 25; 171(3):663-75. PubMed ID: 24125472
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.